REGARD: what can we learn from randomised, open-label, head-to-head studies?

The Lancet Neurology

Volumn 7, Issue 10, 2008, Pages 864-866

  Sørensen, Per Soelberg ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER;

CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; HUMAN; LETTER; MULTIPLE SCLEROSIS; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZATION; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME;

HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 51449088420     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(08)70201-1     Document Type: Letter

References (12)

1. Duquette P., Girard M., Despault L., et al. Interferon beta-1B is effective in relapsing-remitting multiple sclerosis-clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 655-661
2. Jacobs L.D., Cookfair D.L., Rudick R.A., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39 (1996) 285-294
3. Johnson K.P., Brooks B.R., Cohen J.A., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45 (1995) 1268-1276
4. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352 (1998) 1498-1504
5. Comi G., Filippi M., and Wolinsky J.S. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49 (2001) 290-297
6. Mikol D.D., Barkhof F., Chang P., et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7 (2008) 903-914
7. Koch-Henriksen N., Sørensen P.S., Christensen T., Frederiksen J., Ravnborg M., Jensen K., et al. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 66 (2006) 1056-1060
8. The Once Weekly Interferon for MS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology 53 (1999) 679-686
9. Durelli L., Verdun E., Barbero P., et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359 (2002) 1453-1460
10. Panitch H., Goodin D.S., Francis G., et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 59 (2002) 1496-1506
11. O'Connor P., Arnason B., Comi G., et al. Interferon-beta-1b 500 mcg, interferon beta-1b 250 mcg and glatiramer acetate: primary outcomes of the Betaferon®/Betaseron® efficacy yielding outcomes of a new dose study. Neurology 71 (2008) 153-154
12. National Multiple Sclerosis Society. Clinical trials in multiple sclerosis 2007: planned, in progress, recently completed. http://www.nationalmssociety.org/research/clinical-trials/download.aspx?id=224 (Accessed August 24, 2008).